Tamara Rordorf

13.5k total citations
37 papers, 678 citations indexed

About

Tamara Rordorf is a scholar working on Oncology, Otorhinolaryngology and Surgery. According to data from OpenAlex, Tamara Rordorf has authored 37 papers receiving a total of 678 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 18 papers in Otorhinolaryngology and 13 papers in Surgery. Recurrent topics in Tamara Rordorf's work include Head and Neck Cancer Studies (18 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Cancer Diagnosis and Treatment (7 papers). Tamara Rordorf is often cited by papers focused on Head and Neck Cancer Studies (18 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Cancer Diagnosis and Treatment (7 papers). Tamara Rordorf collaborates with scholars based in Switzerland, Spain and United States. Tamara Rordorf's co-authors include Marius Bredell, Kevin J. Harrington, Makoto Tahara, Danny Rischin, Wan Zamaniah Wan Ishak, Thorsten Fuereder, Gilberto de Castro, Nuttapong Ngamphaiboon, Barbara Burtness and Denis Soulières and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Tamara Rordorf

36 papers receiving 666 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tamara Rordorf Switzerland	15	421	218	210	175	92	37	678
Esma Saâda France	15	392 0.9×	170 0.8×	506 2.4×	166 0.9×	62 0.7×	70	874
Milan Vošmik Czechia	17	258 0.6×	174 0.8×	254 1.2×	294 1.7×	59 0.6×	81	771
Zhengxue Han China	15	258 0.6×	328 1.5×	123 0.6×	393 2.2×	49 0.5×	88	761
Ying‐Ju Kuo Taiwan	15	361 0.9×	116 0.5×	69 0.3×	372 2.1×	90 1.0×	39	714
Cristina P. Rodriguez United States	13	482 1.1×	185 0.8×	196 0.9×	423 2.4×	58 0.6×	47	818
Eun Ji Chung South Korea	10	320 0.8×	119 0.5×	96 0.5×	180 1.0×	105 1.1×	26	562
Iris Gluck Israel	15	634 1.5×	369 1.7×	307 1.5×	303 1.7×	173 1.9×	26	1.0k
Kouki Miura Japan	13	525 1.2×	281 1.3×	112 0.5×	473 2.7×	26 0.3×	54	728
Annarita Palomba Italy	15	492 1.2×	88 0.4×	149 0.7×	517 3.0×	21 0.2×	40	812
Yulia Strenov Israel	13	194 0.5×	92 0.4×	74 0.4×	145 0.8×	43 0.5×	19	622

Countries citing papers authored by Tamara Rordorf

Since Specialization

Citations

This map shows the geographic impact of Tamara Rordorf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tamara Rordorf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tamara Rordorf more than expected).

Fields of papers citing papers by Tamara Rordorf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tamara Rordorf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tamara Rordorf. The network helps show where Tamara Rordorf may publish in the future.

Co-authorship network of co-authors of Tamara Rordorf

This figure shows the co-authorship network connecting the top 25 collaborators of Tamara Rordorf. A scholar is included among the top collaborators of Tamara Rordorf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tamara Rordorf. Tamara Rordorf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tahara, Makoto, Richard Greil, Danny Rischin, et al.. (2025). Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study. European Journal of Cancer. 221. 115395–115395. 6 indexed citations

Greil, Richard, Barbara Burtness, Simon Laban, et al.. (2023). 106P Treatment sequencing in PD-L1–positive recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Exploratory analysis of the phase III KEYNOTE-048 study. Immuno-Oncology Technology. 20. 100578–100578. 1 indexed citations

Tahara, Makoto, Danny Rischin, Kevin J. Harrington, et al.. (2022). 659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048. Annals of Oncology. 33. S844–S844. 8 indexed citations

Freiberger, Sandra N., Muriel Brada, Christine Fritz, et al.. (2021). SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets. Neoplasia. 23(5). 473–487. 42 indexed citations

Riesterer, Oliver, Martin Pruschy, Sabine Bender, et al.. (2020). Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study. Radiotherapy and Oncology. 150. 62–69. 3 indexed citations

Greil, Richard, Danny Rischin, Kevin J. Harrington, et al.. (2020). 915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Annals of Oncology. 31. S660–S661. 8 indexed citations

Satoh, Takashi, Mark Mellett, Barbara Meier, et al.. (2019). IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes. Journal of Clinical Investigation. 130(3). 1417–1430. 38 indexed citations

Burtness, Barbara, Kevin J. Harrington, Richard Greil, et al.. (2018). KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Annals of Oncology. 29. viii729–viii729. 97 indexed citations

Finazzi, Tobias, et al.. (2018). Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy. BMC Cancer. 18(1). 395–395. 13 indexed citations

10.

Schneider, Paul M., Dilmurodjon Eshmuminov, Tamara Rordorf, et al.. (2018). 18FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study. BMC Cancer. 18(1). 548–548. 24 indexed citations

11.

Ferris, Robert L., George R. Blumenschein, Jérôme Fayette, et al.. (2018). Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups. International Journal of Radiation Oncology*Biology*Physics. 100(5). 1317–1317. 7 indexed citations

12.

Bredell, Marius, Tamara Rordorf, Sabine Kroiss, et al.. (2017). Denosumab as a Treatment Alternative for Central Giant Cell Granuloma: A Long-Term Retrospective Cohort Study. Journal of Oral and Maxillofacial Surgery. 76(4). 775–784. 56 indexed citations

13.

Harrington, Kevin J., Nicolas Mach, Tamara Rordorf, et al.. (2017). Early safety from phase 1b/3, multicenter, open-label, randomized trial of talimogene laherparepvec (T-VEC) + pembrolizumab (pembro) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): MASTERKEY-232. Annals of Oncology. 28. v394–v394. 9 indexed citations

14.

Rochlitz, Christoph, Roger von Moos, Jürg Bernhard, et al.. (2016). SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. BMC Cancer. 16(1). 780–780. 40 indexed citations

15.

Ernst, Jutta, Kristian Ikenberg, Desirée Schumann, et al.. (2016). Expression of CK19 is an independent predictor of negative outcome for patients with squamous cell carcinoma of the tongue. Oncotarget. 7(46). 76151–76158. 14 indexed citations

16.

Rordorf, Tamara, Ibrahim A. Hassan, Hamdy A. Azim, et al.. (2014). Bone health in breast cancer patients: A comprehensive statement by CECOG/SAKK Intergroup. The Breast. 23(5). 511–525. 14 indexed citations

17.

Studer, Gabriela, Claudia Linsenmeier, Oliver Riesterer, et al.. (2013). Late term tolerance in head neck cancer patients irradiated in the IMRT era. Radiation Oncology. 8(1). 259–259. 14 indexed citations

18.

Studer, Gabriela, Michelle Brown, Marius Bredell, et al.. (2012). Follow up after IMRT in oral cavity cancer: update. Radiation Oncology. 7(1). 84–84. 19 indexed citations

19.

Studer, Gabriela, Tamara Rordorf, & Christoph Glanzmann. (2011). Impact of tumor volume and systemic therapy on outcome in patients undergoing IMRT for large volume head neck cancer. Radiation Oncology. 6(1). 120–120. 7 indexed citations

20.

Opitz, Isabelle, Didier Lardinois, Peter Kestenholz, et al.. (2006). 175 Induction chemotherapy with cisplatine/gemcitabine compared to cisplatin/pemetrexed followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Lung Cancer. 54. S42–S43. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact